Illuminating diabetes via multi-omics: Unraveling disease mechanisms and advancing personalized therapy

Figure 1 Overview of metabolomics approaches, analytical platforms, applications, and challenges. Samples (biofluids, tissues, cells) are collected from individuals with distinct diabetes subtypes (type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes mellitus) and related complications (e.g., diabetic kidney disease, diabetic retinopathy). Researchers can choose targeted vs untargeted metabolomics strategies depending on the objectives (biomarker discovery, mechanism elucidation). Key analytical platforms include liquid chromatography-mass spectrometry, gas chromatography-mass spectrometry and nuclear magnetic resonance, each capturing unique metabolite classes. The figure also highlights the main challenges-such as data complexity, sample variability, and metabolite identification-along with the resulting potential applications in diagnosis, risk stratification, and therapeutic monitoring. LC-MS: Liquid chromatography-mass spectrometry; GC-MS: Gas chromatography-mass spectrometry; NMR: Nuclear magnetic resonance.